EUCTR2013-000797-30-DK
Active, not recruiting
Phase 1
Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation - INSPIRE-AF
Department of Medical Research, Odense University Hospital, Svendborg Hospital0 sitesOctober 8, 2013
DrugsSpirix
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Department of Medical Research, Odense University Hospital, Svendborg Hospital
- Status
- Active, not recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients \= 18 years of age, male or female.
- •Signed written informed consent.
- •Paroxysmal atrial fibrillation on one or more occasions, detected on 12\-lead ECG or Holter monitoring with each AF\-episode lasting \= 30 seconds, within the last 12 months prior to the screening visit, or persistent AF on one or more occasions that has been direct current (DC) cardioverted within the last 12 months prior to the screening visit.
- •Patients with CHA2DS2\-VASc score \= 1 will be encouraged to start anticoagulant treatment, but will not be excluded if there are reasonable reasons not to, i.e. risk of bleeding. Patients can choose between standard anticoagulation therapies, i.e. warfarin or non vitamin\-K oral anticoagulants (NOAC) such as dabigatran, apixaban and rivaroxaban.
- •Women with childbearing potency must use effective contraception (e.g. implants, hormonal depot injections, combined oral contraceptives, intra\-uterine devices or vasectomized partner). Men enrolled in this study must agree to use adequate barrier birth control measures during the treatment period of the study. Reliable contraception should be maintained throughout the study and for 30 days after study drug discontinuation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 90
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •Chronic atrial fibrillation.
- •Previous radiofrequency ablation for atrial fibrillation or previous surgical treatment of atrial fibrillation, i.e. MAZE or His\-ablation.
- •Heart failure (New York Heart Association (NYHA) class \= II and/or LVEF less than 40%).
- •Severe coronary artery disease (acute myocardial infarction within 6 months prior to the screening visit, previous coronary artery bypass graft (CABG) or stabile angina pectoris (Canadian Cardiovascular Society (CCS) class \=II).
- •Stroke or transient ischemic cerebral attack within 6 months prior to the screening visit.
- •Pregnant women or women of childbearing potential not on adequate birth control. Only women with a highly effective method of contraception (oral contraception, intra\-uterine device or sterile women) can be randomized.
- •Presence of severe and hemodynamically significant valvular heart disease.
- •Any disease that limits life expectancy to less than 1 year.
- •Hepatic insufficiens classified as Child\-Pugh B or C.
- •Participation in another clinical trial, either within the last 30 days or ongoing.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Inhibition of Aldosterone in Patients With Chronic Renal DiseaseKidney Failure, ChronicNCT00430924Lene Boesby42
Completed
Not Applicable
Does aldosterone blockade improve endothelial dysfunction in patients with coronary artery disease but without heart failure?Coronary artery diseaseCirculatory SystemISRCTN70010120niversity of Dundee (UK)88
Active, not recruiting
Phase 1
The effect of aldosterone inhibition on proteinuria in patients with progressive renal disease.Patients with chronic nephropathy and proteinuria over 0,5 g/24 hrs are to be given an inhibitor of aldosterone. Theory tells that aldosterone plays an active role in nephropathy and if that can be inhibited patients with chronic renal diseases may prolong their pre-dialysis period of time.MedDRA version: 8.1Level: SOCClassification code 10038359Term: Renal and urinary disordersEUCTR2006-004411-21-DKOrganisation name was not entered25
Completed
Not Applicable
Effects of aldosterone antagonism on microvascular function in obese individualsNL-OMON45212niversiteit Maastricht60
Completed
Phase 3
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)ADPKDNCT01853553University of Colorado, Denver61